Pancreatic Cancer Research

ResearcherUniversity of Oklahoma Health Sciences CenterActive in the last 2 years

Min Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4026-0440; OpenAlex author ID A5100713494. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16. Co-author DOI 10.1172/jci195970↗
  2. ZIP4 confers resistance to zinc deficiency-induced apoptosis in pancreatic cancer. Last author DOI 10.4161/cc.28111↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yumeng Hu · 1 shared paper, 2025 · strength 0.22
  2. Shaobo Zhang · 1 shared paper, 2025 · strength 0.22
  3. Mingyang Liu · 1 shared paper, 2025 · strength 0.22
  4. Fangxia Wang · 1 shared paper, 2025 · strength 0.22
  5. Zhijun Zhou · 1 shared paper, 2025 · strength 0.22
  6. Haoran Qi · 1 shared paper, 2025 · strength 0.22
  7. Wenming Wu · 1 shared paper, 2025 · strength 0.22
  8. Yu‐Qing Zhang · 1 shared paper, 2014 · strength 0.05
  9. Xiaobo Cui · 1 shared paper, 2014 · strength 0.05
  10. Jingxuan Yang · 1 shared paper, 2014 · strength 0.05
  11. Sushovan Guha · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.